ArticleScientific reports2025
Association of lipid accumulation product with mortality in patients with diabetes mellitus.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of Serum Lipids with 10-Year CVD and All-Cause Mortality in Iranian Adults: A Prospective Cohort Study.Archives of Iranian medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lipid accumulation product (LAP) is associated with increased risk of metabolic diseases and cardiovascular disease. However, its relationship with all-cause mortality and cardiovascular mortality among diabetes mellitus (DM) patients remains unclear. This study aims to explore the associations between LAP and mortality outcomes in patients with DM. This study included 10,944 patients with DM from the national health and nutrition examination survey. LAP was calculated using waist circumference and triglyceride levels, according to gender-specific formula. All-cause and cardiovascular mortality were determined through linkage with the national death index database through December 31, 2019. Multivariable Cox proportional hazard models examined the associations between LAP and mortality. Restricted cubic splines were used to investigate potential non-linear relationships. A series of subgroup and sensitivity analyses were also performed to evaluate robustness of our results. During a median follow-up of 86 months, 1,508 all-cause deaths and 413 cardiovascular deaths were recorded. Higher LAP levels were associated with an increased risk of both all-cause mortality (highest vs. lowest quartile: hazard ratio [HR] 1.69, 95% CI 1.39-2.05) and cardiovascular mortality (HR 2.02, 95% CI 1.36-3.00). Non-linear relationships were observed between LAP and both all-cause and cardiovascular mortality. Notably, interactions between LAP and both age and diabetes duration were found in relation to all-cause and cardiovascular mortality. The results remained consistent after a series of subgroup and sensitivity analyses. The results didn't significantly change according to a series of subgroup and sensitivity analyses. Higher LAP levels were associated with increased risks of all-cause and cardiovascular mortality in patients with DM. These findings suggest that LAP could serve as a valuable predictor for mortality risk assessment in diabetic patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.